文献速递主动脉疾病外周动脉疾病

意大利多中心注册研究:主髂动脉闭塞性疾病原发腔内治疗结局

Outcomes From the Multicenter Italian Registry on Primary Endovascular Treatment of Aortoiliac Occlusive Disease.
PubMed 文献 · J Endovasc Ther · 2019-07-22

该回顾性多中心观察队列纳入713例主髂动脉闭塞性病变患者,均接受原发支架置入,技术成功率达99%,院内死亡率0.6%;1年和2年原发通畅率分别为96%和94%,覆盖支架与再干预需求增加相关,COPD与原发通畅率降低相关。

要点

  • 原发支架治疗主髂动脉闭塞性疾病2年原发通畅率达94%,不受病变复杂程度影响。
  • 覆盖支架使用与再干预需求增加独立相关(HR 1.4)。
  • COPD与原发通畅率降低独立相关(HR 3.7)。

核心结论

  • 原发支架腔内治疗主髂动脉闭塞性疾病2年通畅率满意,无论病变复杂程度如何,几乎所有TASC病变在适合时均应考虑原发腔内干预。

主要发现

  • 技术成功708例(99%),院内死亡0.6%(4例),中位随访11个月(范围0-42)。
  • 1年原发通畅率96%(95%CI 94%-97%),2年94%(95%CI 91%-96%)。
  • 1年二期通畅率99%(95%CI 97%-99%),2年98%(95%CI 95%-99%)。
  • 1年免于再干预率98%(95%CI 96%-99%),2年97%(95%CI 94%-98.5%)。
  • Cox回归显示覆盖支架与再干预需求增加相关(HR 1.4,95%CI 1.10-1.74,p=0.005),COPD与原发通畅率降低相关(HR 3.7,95%CI 1.25-10.8,p=0.018)。

关键数值与推荐

  • 病变按TASC II分类:A型104例(15%),B型171例(24%),C型170例(24%),D型268例(37%)。
  • 治疗指征:间歇性跛行406例(57%),严重肢体缺血307例(43%)。

临床怎么用

  • 对于适合的主髂动脉闭塞性病变,原发支架置入可作为有效治疗选择,包括复杂TASC病变。
  • 使用覆盖支架时需警惕再干预风险增加,COPD患者需关注原发通畅率可能降低。

局限性

  • 回顾性观察性设计。
  • 中位随访仅11个月,部分患者随访时间较短(范围0-42个月)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose: To report the results of endovascular treatment of iliac and complex aortoiliac occlusive disease (AIOD) in a multicenter Italian registry. Materials and Methods: A retrospective, multicenter, observational cohort study analyzed 713 patients (mean age 68±10 years; 539 men) with isolated iliac and complex aortoiliac lesions treated with primary stenting between January 2015 and December 2017. Indications for treatment were claudication in 406 (57%) patients and critical limb ischemia in 307 (43%). According to the TransAtlantic Inter-Society Consensus II (TASC) classification, the lesions were categorized as type A (104, 15%), type B (171, 24%), type C (170, 24%), and type D (268, 37%). Early (<30 days) endpoints included mortality, thrombosis, and major complications. Late major outcomes were primary and secondary patency and freedom from reintervention as estimated by Kaplan-Meier analysis; estimates are given with the 95% confidence intervals (CIs). Associations between baseline variables and primary patency were sought with multivariate analysis; the results are presented as the hazard ratio (HR) and 95% CI. Results: Technical success was achieved in 708 (99%) lesions; in-hospital mortality was 0.6% (n=4). The median follow-up was 11 months (range 0-42). The estimated primary patency rate was 96% (95% CI 94% to 97%) at 1 year and 94% (95% CI 91% to 96%) at 2 years. The estimated secondary patency was 99% (95% CI 97% to 99%) at 1 year and 98% (95% CI 95% to 99%) at 2 years. The estimated freedom from reintervention was 98% (95% CI 96% to 99%) at 1 year and 97% (95% CI 94% to 98.5%) at 2 years. Cox regression analysis demonstrated that the application of a covered stent was associated with an increased need for reintervention (HR 1.4, 95% CI 1.10 to 1.74, p=0.005). Chronic obstructive pulmonary disease was associated with decreased primary patency (HR 3.7, 95% CI 1.25 to 10.8, p=0.018). Conclusion: Endovascular intervention with primary stent placement for aortoiliac occlusive disease achieved satisfactory 2-year patency regardless of the complexity of the lesion. Almost all TASC lesions should be considered for primary endovascular intervention if suitable.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Piffaretti G, Fargion AT, Dorigo W, et al. Outcomes From the Multicenter Italian Registry on Primary Endovascular Treatment of Aortoiliac Occlusive Disease. J Endovasc Ther. 2019. PMID: 31331235. doi:10.1177/1526602819863081

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。